Expansion—This year, we revealed plans to create and expand four innovation centers. In New York City and San Diego, we plan to expand our current research and
development centers. This will allow us to strengthen existing partnerships with universities and
institutes in those areas. Soon, we'll also begin building our newest innovation center in Cambridge, Massachusetts—a strategic location that will help attract top scientists and bioengineers, as
well as enhance our local business development presence. And, at home in Indianapolis, we will break ground on a new lab
dedicated to researching small molecules in 2016.
Partnerships—Collaboration remains a critical component of development and discovery. We continue to work with AstraZeneca to explore new therapies for a variety of diseases. In addition to AstraZeneca, we look forward to continuing our collaboration with the Dominantly Inherited Alzheimer Network to find a treatment for Alzheimer's disease.
Development—Lilly remains dedicated to Clinical Innovation and advancing treatments through research. Drawing on our team member’s diverse background, this group of Lilly employees is tackling our most pressing health issues with a fresh perspective. And in 2015, they expressed their gratitude to all those who have participated in clinical trials.
Lilly remains firmly committed to improving health through both the discovery of new medicines and the expansion of innovative research centers and partnerships, innovation and creating new treatments. We look forward to the promise of even more discovery.